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Background: Atorvastatin can downregulate the expression of receptor for advanced glycation end products
(RAGE) in the aortas of diabetic rats. However, its effect on healthy rats remains unclear. The aim of this study was
to observe the direct impact of atorvastatin on advanced glycation end products- (AGEs) induced RAGE expression
in healthy Sprague Dawley (SD) rats.
Methods: SD rats received AGE-BSA (20 mg/kg/day or 40 mg/kg/day), dual treatment (AGE-BSA 40 mg/kg/day and
atorvastatin 20 mg/kg/day) or no treatment for 12 and 24 weeks, respectively. The deposition of AGEs and expression
of RAGE in the animals’ aortas were assessed by Quantitative RT-PCR, immunohistochemistry, and western-blot tests.
Serum levels of AGEs were measured using ELISA.
Results: AGE-BSA upregulated the serum level of AGEs, deposition of AGEs, and expression of RAGE in aortas in a
time- and dose-dependent way that can accelerate the development and progression of atherosclerosis. These
upregulations could be significantly attenuated by atorvastatin in the absence of its lipid-lowering effects. These
data provide further evidence for the novo mechanism of atorvastatin’s pleiotropic effect.
Conclusion: Atorvastatin has a direct inhibitory effect on AGEs-RAGE expression in healthy SD rats. These potential
pleiotropic vasculoprotective effects are independent of effects on glucose and lipid control.
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Hyperglycaemia drives non-enzymatic glycation and oxi-
dation of proteins and lipids, which enhances irreversible
formation of advanced glycation end products (AGEs)
[1]. Accumulation of preformed AGEs in the vessel wall
has been shown to promote diabetic vascular diseases
[2]. The receptor for AGEs (RAGE) is a multi-ligand re-
ceptor that mediates the action of AGEs.
RAGE was initially isolated from the lung, but is also
expressed on the surface of vascular endothelial cells,
smooth muscle cells, and macrophages [3]. Accumulat-
ing evidence suggests that RAGE plays a pivotal role in
promoting inflammatory processes and endothelial acti-
vation, which accelerates atherosclerosis in patients with* Correspondence: bfeng2010@hotmail.com
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unless otherwise stated.diabetes [4]. Binding of AGEs to RAGE activates multiple
intracellular signalling pathways, including p21ras, which
recruits downstream targets such as mitogen-activated
protein kinases (MAPK) and activates nuclear factor kap-
paB (NF-κB) [5,6]. The AGEs-RAGE interaction augments
inflammatory responses and leads to vascular dysfunction
and monocyte activation [7]. Diabetes-associated athero-
sclerotic lesions display increased accumulation of RAGE
ligands and enhanced expression of RAGE [4,8].
3-Hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase
inhibitors, also known as statins, are commonly used for
the treatment of dyslipidaemia. A large number of studies
have demonstrated that statin therapy is associated with a
reduction in cardiovascular events in people both with and
without diabetes [9-12]. While a reduction in low-density
lipoprotein- cholesterol (LDL-C) was observed in many
of these studies, it is now considered that statins also
mediate pleiotropic antiatherogenic effects that areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Xu et al. Diabetology & Metabolic Syndrome 2014, 6:102 Page 2 of 10
http://www.dmsjournal.com/content/6/1/102partially independent of their cholesterol-lowering ef-
fects and may contribute to their efficacy in reducing
cardiovascular events. These cholesterol-independent
effects include improving endothelial function, attenu-
ating vascular and myocardial remodelling, inhibiting
vascular inflammation and oxidation, and stabilizing
atherosclerotic plaques [13-15].
In our previous study, we found that atorvastatin can
significantly downregulate the expression of RAGE in
aorta of diabetic Goto Kakisaki (GK) rats [16]. Those
data demonstrated a novel “pleiotropic” activity of ator-
vastatin in reducing the risk of cardiovascular diseases
by targeting RAGE expression. However, no work has
been done on the direct effects of atorvastatin on the
formation and deposition of AGEs and the expression of
RAGE in healthy animal models. In the present study,
we provided novel data that suggested atorvastatin could
decrease the AGEs-induced increase in serum level of
AGEs and suppress the expression of RAGE of aorta in
Sprague Dawley (SD) rat models in euglycemic condi-
tions. These results will further confirm the pleiotropic
activity of atorvastatin by targeting RAGE.
Methods
Preparation of AGEs
Bovine serum albumin (BSA) and D-glucose were dis-
solved in PBS (pH 7.2–7.4): the final concentrations of
BSA and D-glucose were 5 g/L and 50 mmol/L, respect-
ively. EDTA was added to a final concentration of
0.5 mmol/L to reduce oxidation. Penicillin (100 U/L)
and streptomycin (100 μg/ml) were added to the reac-
tion mixture to prevent bacterial contamination. The re-
action mixture was filtered through 0.22 μm filter and
then incubated at 37°C for 12 weeks.
At the end of the incubation period, the reaction mix-
ture was dialyzed against sterilized PBS (pH 7.2–7.4) to
remove the unconjugated glucose. The glucose level in
the dialyzate was <0.03 mmol/L. The reaction mixture
was measured in a fluorospectrophotometer with an ex-
citation wave of 370 nm, and the maximum absorption
peak was measured at 440 nm to verify that the mixture
was glycated-BSA. Finally, the glycated-BSA was freeze-
dried and stored at 4°C.
Animal experiment and sample collection
Male SD rats (SLRC Laboratory Animal centre, Shang-
hai, China) weighing 200–250 g (starting age 8 weeks)
were divided into five groups. Group A ate standard
chow (n = 10). Group B had a high-fat diet containing
69.13% standard chow to which we added 1.37% choles-
terol, 0.5% bile salts, 9% sugar, and 20% lard. (n = 10).
Group C ate the high-fat diet plus AGEs with glycated-
BSA 20 mg/kg body weight per day through intraperito-
neal injection (n = 10). Group D ate the high-fat dietplus AGEs with glycated-BSA 40 mg/kg body weight per
day through intraperitoneal injection (n = 10). Group E
consumed the high-fat diet plus AGEs with glycated-
BSA 40 mg/kg body weight per day through intraperito-
neal injection and atorvastatin (Lipitor, Pfizer Ireland
Pharmaceuticals) 20 mg/kg/day, through intragastric ad-
ministration (n = 10).
We chose SD rats as the animal models because of
their normal glucose levels without obvious insulin re-
sistance compared with the Goto Kakisaki (GK) rats
used in our previous study. We chose the dose of ator-
vastatin mainly on the basis of our previous study [16].
As one of a series of experiments, we chose the same
dose of atorvastatin for comparisons. It is higher than
the human dose (1.1 mg/kg per day) recommended for
treatment of hypercholesterolemia [17], but consistent
with the pharmacokinetic data indicating a higher meta-
bolic rate of the drug in rodents [18].
Body weight was measured weekly. At the end of the
12th and the 24th week, five rats per group were
anaesthetised by an intraperitoneal injection of pento-
barbitone sodium (100 mg/kg body weight) (Euthatal;
Sigma-Aldrich, Castle Hill, NSW, Australia). Blood
was collected from the left ventricle and centrifuged
(6,000 × g), and plasma samples were stored at −20°C for
subsequent analysis. Animals were sacrificed and the aor-
tas were rapidly dissected and snap frozen in liquid nitro-
gen and stored at −80°C or stored in buffered formalin
(10%, vol./vol.) for subsequent measurement. All animal
experiments were conducted according to the protocol
approved by the Animal Committee of the Animal Center
of East Hospital, Tongji University.Measurement of serum glucose, lipids, and AGEs
Serum glucose levels were measured by the glucose oxi-
dase method (Sigma, MO). Total cholesterol, triglycerides,
LDL-C and high-density lipoprotein-cholesterol (HDL-C)
levels were measured using a kit from Sigma Diagnostics.
The serum levels of AGEs were determined using com-
mercially available enzyme linked immunosorbent assay
(ELISA) kits (Xitang Bio Technology Co, Shanghai, China)
according to the manufacturer’s instructions.Quantitative real-time PCR analysis
Total RNA was isolated with the trizol method and depu-
rated with an RNAeasy kit (Invitrogen, CA). RNA was
stored at −80°C until reverse transcription was performed.
An aliquot (1 μg) of extracted RNA was reverse-transcribed
into the first strand of complementary DNA (cDNA) at
42°C for 40 min, using 100 U/ml reverse -transcriptase
(Takara Biochemicals, Shiga, Japan) and 0.1 μM of
oligo (dt)- adapter primer (Takara) in a 50 ul reaction
mixture.
Xu et al. Diabetology & Metabolic Syndrome 2014, 6:102 Page 3 of 10
http://www.dmsjournal.com/content/6/1/102Real-time polymerase chain reaction (PCR) was car-
ried out with an ABI Prism 7000 Real-Time PCR system,
using the DNA-binding dye SYBER Green I for the de-
tection of PCR products. The reaction mixture (RT-PCR
kit, Takara) contained 12.5 μl Premix Ex Tag, 2.5 μl
SYBER Green I, custom-synthesized primers, ROX refer-
ence dye, cDNA (equivalent to 20 ng total RNA) to give
a final reaction volume of 25 μl. Primers were as follows:
GAPDH: sense 5’AGAGGAGAGGAAGGCCCCAGA
3’, antisense 5’GGCAAGGTGGGGTTATACAGG 3’;
RAGE: sense 5’GACAACTTTGGCATCGTGGA 3’,
antisense 5’ATGCAGGGATGATGTTCTGG 3’.
The PCR settings were as follows: initial denaturation of
30 s at 95°C, followed by 40 cycles of amplification for 5 s
at 95°C and 34 s at 60°C, with subsequent melting curve
analysis increasing the temperature from 60°C to 95°C. To
quantify RAGE gene expression, the RAGE mRNA level
was normalized by internal GADPH mRNA.
Hematoxylin and eosin (HE) staining and
immunohistochemistry
Thoracic aorta sections were rehydrated and placed in Gill’s
c2 hematoxylin (Medical reagent company, Shanghai, China)
and then transferred to an eosin Y solution (Medical reagent
company, Shanghai, China). After staining, the sections were
dehydrated through the alcohol series back to xylene and a
coverslip was mounted to each slide with Permount.
Immunostaining of AGEs and RAGE was performed
using the Vectastain Elite ABC Mouse/Rabbit IgG kit
based on an avidin/biotin/peroxidase system (Boster Bio-
technology Co. Ltd, Wuhan, China) according to the
manufacturer’s instructions. Briefly, the sections were in-
cubated with 5% bovine serum albumin in PBS at room
temperature for 30 min to block nonspecific binding of
the second antibody and then reacted with the primary
antibodies against AGEs (1:50, Santa Cruz Biotechnology)
or RAGE (1:50, Santa Cruz Biotechnology) at 4°C over-
night. Then they were exposed to the biotinylated second-
ary antibody at room temperature for 30 min. After
washing in PBS, the specimens were incubated with an
avidin-biotin-peroxidase complex at room temperature
for 30 min. Deposition was visualized by treating the sec-
tions with DAB. The sections were viewed and photo-
graphed with an Olympus XI 70 microscope and digital
imaging system (Olympus Optical, Tokyo, Japan). Image
Pro Plus 6.0 was used to analyse the average of optical
density (AOD) in the positive staining area.
Western blot analysis
Aortas were dissected and used to analyse protein levels
by western blot. The lysates (30 μg protein) wereseparated by 10% SDS-PAGE, transferred to a PVDF
membrane (Millipore), blocked with 5% non-fat dry milk
for 60 min, and probed overnight with antibodies at 4°C.
The blots were incubated with HRP-conjugated anti-IgG
for 1 h at 37°C. We detected protein bands using chemilu-
minescence reagent Amersham ECL plus (GE Healthcare,
Buckinghamshire, UK). Relative intensities of protein bands
were analysed by Gel-Pro Analyzer software. Antibodies
against RAGE (1:1000 dilution) and β-actin (1:1000 dilu-
tion) were purchased from Cell Signaling, USA.
Statistical analysis
All data were expressed as mean ± SD. Kruskal-Wallis
one-way analysis of variance was used to assess the dif-
ferences between groups using SPSS 13.0 software. We
considered values of P < 0.05 statistically significant.
Results
Metabolic parameters
At the end of the 12th week, the body weights of rats in
Groups C and D were higher as compared to other
groups, but that changes were statistically insignificant.
But at the end of the 24th week, a significant increase in
body weight in Group D was observed (P < 0.05). Serum
glucose levels and LDL-C levels were not different
among all five groups at both the 12th week and the
24th week (Table 1).
The change of serum AGEs levels
Compared with Group A, there was significant increase
(about double) in the serum AGEs levels in Group B at
the 12th and the 24th weeks (52.85 ± 3.08 vs 25.78 ± 4.09
at the 12th week,49.91 ± 4.70 vs 21.69 ± 3.88 at the 24th
week,P < 0.05). AGEs-BSA treatment induced a further
increase compared with Group B, and at the 24th week,
the high-dose AGEs-BSA treated group (Group D) had
the highest level of all groups with statistical signifi-
cance, compared to Group A (about 3.3 times as much)
(72.02 ± 4.37 vs 21.69 ± 3.88,P = 0.002) and Group B
(about 1.4 times) (72.02 ± 4.37 vs 49.91 ± 4.70,P = 0.009).
Atorvastatin treatment reduced the serum AGEs level
(Group E) compared with group D by a 26% change with
statistical significance at the 24th week (53.43 ± 3.05 vs
72.02 ± 4.37,P = 0.013). AGEs levels in Group E were not
significantly different compared with Group B, but still
higher than Group A about double (53.43 ± 3.05 vs
21.69 ± 3.88, P = 0.006) (Figure 1).
Accumulation of AGEs in aortic wall
The presence of AGEs in aortic walls was immunohisto-
chemically examined in the tissue specimens of the aor-
tas from the five experimental groups. There was no
obvious positive immunostaining of AGEs in each group
at the 12th week (Figure 2 A1-E1). At the 24th week,
Table 1 Metabolic parameters of SD rats in different groups
Body weight Serum glucose LDL-c
12th week 24th week 12th week 24th week 12th week 24th week
Group A 603.40 ± 37.72 750.20 ± 40.24 5.62 ± 0.28 6.29 ± 0.24 2.78 ± 0.62 1.81 ± 0.38
Group B 621.25 ± 46.82 720.36 ± 33.69 6.18 ± 0.67 5.79 ± 0.66 1.74 ± 0.58 1.79 ± 0.52
Group C 630.13 ± 28.41 784.35 ± 38.53 5.98 ± 1.16 5.72 ± 0.69 2.08 ± 0.37 2.24 ± 0.42
Group D 626.38 ± 32.32 806.61 ± 48.25* 5.95 ± 0.92 6.24 ± 0.75 2.04 ± 1.01 2.08 ± 0.85
Group E 616.13 ± 42.38 771.5 ± 40.08 5.62 ± 0.90 6.20 ± 0.28 2.74 ± 0.29 2.72 ± 0.36
Group A: absolute controls, (n = 10); Group B: high fat diet (n = 10); Group C: high fat diet plus AGEs with glycated-BSA 20 mg/kg body weight (n = 10); Group D:
high fat diet plus AGEs with glycated-BSA 40 mg/kg (n = 10)#Group E: high fat diet plus AGEs with glycated-BSA 40 mg/kg and atorvastatin. Each value represents
the mean ± S.D. * = p < 0.05 vs. other groups at the end of 24th week.
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(Figure 2 C2-D2), especially in Group D (Figure 2 D2).
Atorvastatin attenuated AGEs accumulation significantly
compared with Group D (Figure 2 E2).
Then the AOD in the positive staining area was ana-
lysed by software. At the 24th week, the accumulation of
AGEs had a further increase in Group C and Group D
(about double) with statistical significance, compared
with Group A (2.88 ± 0.21 vs 1.53 ± 0.22,2.99 ± 0.28 vs
1.53 ± 0.22,respectively; P < 0.001) and about 1.6 times
that of Group B (2.88 ± 0.21 vs 1.76 ± 0.19; 2.99 ± 0.28 vs
1.76 ± 0.19,respectively; P = 0.001). Atorvastatin reduced
the presence of AGEs without statistical significance
compared with Group D at the 24th week (Figure 3).
Expression of RAGE in mRNA levels in the aortic wall
Compared with Group A, the expression of RAGE mRNA
was significantly increased in Groups B, C, and D at theFigure 1 Serum AGEs levels in different groups at the end of
the 12th week and the 24th week respectively. *compared with
group A, P < 0.05; △compared with group A and group B, P < 0.05;
§compared with group D, P < 0.05. Group A: absolute controls, (n = 10);
Group B: high fat diet (n = 10); Group C: high fat diet plus AGEs with
glycated-BSA 20 mg/kg body weight (n = 10); Group D: high fat diet
plus AGEs with glycated-BSA 40 mg/kg (n = 10)#Group E: high fat diet
plus AGEs with glycated-BSA 40 mg/kg and atorvastatin.12th week (P < 0.01). At the 24th week, RAGE mRNA
level in Group D increased around 14 times compared
with that in Group A and B (187.16 ± 16.33 vs 13.08 ±
2.34; 187.16 ± 16.33vs 13.87 ± 4.68,respectively; P < 0.01)
and about 3 times with that in Group C (187.16 ± 16.33 vs
65.90 ± 8.87; P = 0.002). In the atorvastatin-treated group,
however, RAGE mRNA levels were significantly downreg-
ulated to a level comparable to those observed in the nor-
mal Group A and high-fat diet Group B at the 24th week
(Figure 4).
Expression of RAGE in protein levels in the aortic wall
Immunohistochemistry was used to observe expression
of RAGE in aortas. Both at the 12th week and the 24th
week, the expression of RAGE was higher in Group B
than Group A. The AGEs-BSA treated groups (C and D)
had higher expressions of RAGE than Group B. At the
24th week, deeper staining and more enlarged positive
areas were observed in these five groups than at the
12th week. Atorvastatin reduced the expression of
RAGE, compared with Group D (Figure 5).
The quantitative determination of RAGE in aorta was de-
tected by western blot. There were no significant differences
among five groups at the 12th week. At the 24th week, the
expression of RAGE was significantly higher in Groups C
and D than Group A (13.04 ± 2.17 vs 1.07 ± 0.02; P = 0.023
and 16.04 ± 1.36 vs 1.07 ± 0.02; P = 0.003, respectively) and
Group B (13.04 ± 2.17 vs 4.92 ± 1.98; P = 0.032 and 16.04 ±
1.36 vs 4.92 ± 1.98; P = 0.008, respectively). Atorvastatin sig-
nificantly suppressed the expression of RAGE at the 24th
week with about 66% decrease compared with Group D
(5.45 ± 1.84 vs 16.04 ± 1.36,P = 0.008) (Figure 6).
Morphological examination of aortas
The general morphology of aortas in all 5 groups at the
12th week and the 24th week remained relatively con-
stant throughout the study.
Discussion
Statins may be able to reduce cardiovascular events by
mechanisms other than their ability to lower the level of
Figure 2 Immunohistochemical staining of AGEs in aortic wall. A1-E1, Group A-Group E at the end of the 12th week; A2-E2, Group A-Group
E at the end of the 24th week. The presence of antigen is indicated by a red-brownish color which was labeled by arrows. Immunoreactivity was
positive in the intima. Original magnification is × 200 for all photographs. L: lumen; I: intima; A: adventitia.
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Figure 3 AOD of the positive staining area of AGEs in different
groups at the end of the 24th week. *compared with group A
and group B, P < 0.05.
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thermore, there is a growing body of evidence that sta-
tins can decrease the serum AGEs levels and expression
of RAGE in diabetic aortas with atherosclerotic plaque
[21-23]. This effect is supposed to be a novel molecular
mechanism of statin’s pleiotropic actions.
Previously we have demonstrated, using the diabetic
GK rats, that the RAGE expression in diabetic rats was
significantly reduced by treatment with atorvastatin in-
dependent of glycaemic and lipid control in the very
early stage of atherosclerosis, possibly through an epi-
genetic mechanism [16]. However, nearly all prior stud-
ies have been done in diabetic animal models and
cannot exclude the effects of interference factors such as
the level of blood glucose on the results. Therefore these
studies cannot provide exact evidence whether statinsFigure 4 Expression of RAGE in mRNA level of different groups
at the end of the 12th week and the 24th week respectively.
*compared with group B, P < 0.05; △compared with other four
groups, P < 0.05; §compared with group C and group D, P < 0.05.can inhibit the expression of RAGE directly in tissues of
arteries. Therefore, in present study, we chose healthy
SD rats treated with AGEs to simulate the diabetic
pathological changes in arteries induced by AGEs to ex-
clude the interference factors and to determine the dir-
ect effects of atorvastatin on regulation of AGEs and
RAGE.
Although we divided the SD rats into a standard chow
group and high fat diet groups and treated some of them
by atorvastatin or AGEs, unexpectedly there were still
no significant differences in glucose levels and lipid pro-
file levels among these five groups. All the changes in
this study were independent from glycaemic and lipid
control.
In the present study, serum AGEs levels and the accu-
mulation of AGEs in aortas were significantly increased
by AGEs induction in a dose- and time-dependent man-
ner. Concentrations of circulating AGEs correlate to the
severity of coronary artery disease and adverse clinical
outcomes [24]. Atorvastatin can reduce the serum level
of AGEs in a time-dependent and a cholesterol-lowering
independent manner; the exact mechanisms are unclear.
Oxidative stress participates in the formation of AGEs,
which are by themselves a source of free-radical super-
oxide generation as well [25,26]. Furthermore, hydroxyl
metabolites of atorvastatin have been shown to have
anti-oxidative properties [27].
Our previous study suggests that atorvastatin can im-
prove the oxidative stress induced by AGEs. The present
findings suggest that atorvastatin may decrease serum
AGEs levels via its anti-oxidative property. On the other
hand, atorvastatin may reduce the absorption of exogen-
ous AGEs through peritoneal capillary networks and the
intestinal canal through its anti-inflammatory and anti-
oxidative properties, which can reduce the inflammatory
action and oxidative stress of the intestinal wall [28,29].
This may be another possible mechanism to explain the
effect of atorvastatin on decreasing serum AGEs levels.
In spite of the obvious reduction of serum AGEs level,
we did not find a significant reduction of accumulation
of AGEs in aorta in Group E, treated with atorvastatin,
compared with Group D. AGEs slowly degrade and re-
main for a long time in diabetic vessels even after gly-
caemic control and oxidative stress conditions have
improved [30]. Therefore, the phenomenon of so-called
metabolic memory could be explained, in part, by AGEs
[31]. In other words, the accumulation of AGEs on aor-
tas may not be easily reversed by short-term statin
therapy.
There is a growing body of evidence that RAGE may
play a pro-atherogenic role in diabetic arteries [32,33].
Our data showed that the expression of RAGE on aortas
significantly increased in AGEs-treated groups, and this
increase correlated with time, course, and concentration
Figure 5 Expression of RAGE in aortic wall of different groups at the end of the 12th week and the 24th week by immunohistochemical
staining. A1-E1, Group A-Group E at the end of the 12th week; A2-E2, Group A-Group E at the end of the 24th week. The presence of antigen is
indicated by a red-brownish color which was labeled by arrows. Original magnification is × 200 for all photographs. L: lumen; I: intima; A: adventitia.
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sion of RAGE on aortas both in the mRNA and protein
levels, which is in line with our previous observations
[16]. This effect of atorvastatin was partly independent
of the reduction of AGEs accumulation on aortas.Excluding other interference factors of hyperglycaemia
in our present study, we can speculate that atorvastatin
downregulated the expression of RAGE partly by redu-
cing the serum AGEs levels and blocking the AGEs-
RAGE positive feedback loop.
Figure 6 Expression of RAGE in protein level of different
groups at the end of the 12th week and the 24th week
respectively. *compared with group C and group D, P < 0.05.
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inhibit gene expression of RAGE directly. There is a
growing body of evidence that statins could inhibit
plaque RAGE expression in type 2 diabetes [23,34,35].
Furthermore, our previous study demonstrated that ator-
vastatin suppressed the AGE/RAGE pathway by a gene
targeting mechanism in diabetic atherosclerosis.
In the present study, we demonstrated that atorva-
statin can downregulate RAGE expression in normal
conditions without type 2 diabetes or atherosclerosis.
These results are not only in accordance with our previ-
ous study, but also complement previous results. These
data can provide further evidence for the novo mechan-
ism of atorvastatin’s pleiotropic effect.
Notably, the high-fat diet raised the serum level of
AGEs and expression of RAGE in spite of a lack of
change in the serum level of cholesterol. In our previous
study, we found that a high-fat diet could promote the
oxidative stress that may increase the formation of
AGEs.
In addition, treatment of AGEs can increase the body
weight of SD rats, although this has rarely been reported
in previous studies, and the specific mechanism was un-
clear. One study found that weight increases wereassociated with skeletal muscle immunostaining for
AGEs, RAGE, and oxidation injury [36]. The AGEs-
RAGE axis, oxidative stress, weight gain, and insulin re-
sistance may correlate with each other, and further study
should explore this area.
There was no change in the morphology of the aortas
in the five groups, which was in accordance with our
previous study [16]. This shows that atorvastatin can
downregulate the AGEs-RAGE axis in the very early
stages of atherosclerosis, before its therapeutic improve-
ment of the atherosclerotic lesions can be detected his-
tologically. Thus, our data demonstrate there would be
more benefits for diabetic patients from using atorva-
statin earlier at a full, effective dose.
Conclusions
The present results demonstrate the direct inhibitory ef-
fects of atorvastatin on AGEs-RAGE expression in
healthy SD rats. These potential pleiotropic vasculopro-
tective effects are independent of effects on glucose and
lipid control. This study provides strong evidence for the
early use of atorvastatin in diabetes-associated athero-
sclerosis; this agent has the potential to exert superior
long-term vasculoprotection. Future studies should be
done to determine the exact molecular mechanisms and
signalling pathways of the effects of atorvastatin on
AGEs-RAGE expression.
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